AI in Drug Discovery and Development Market to Reach USD 48.04 Billion by 2035, Driven by Generative AI, Precision Medicine & Faster Drug Development

The global AI in Drug Discovery and Development Market reached USD 7.39 billion in 2025 and is expected to reach USD 48.04 billion by 2035, growing at a CAGR of 18.50% during the forecast period 2026-2035. The market is gaining momentum due to increasing adoption of artificial intelligence across drug research, rising demand for faster and more cost-efficient drug development, and growing use of machine learning for target identification, molecule screening, and drug optimization. Advances in AI-driven analytics and computational drug discovery are further supporting market expansion.

A major shift toward AI-powered, data-driven, and accelerated drug discovery is creating new opportunities across pharmaceutical and biotechnology applications. Increasing integration of AI with genomic data, molecular modeling, predictive analytics, and automated screening is helping researchers improve decision-making and streamline complex development processes. The market is poised for strong expansion through 2035 as AI becomes increasingly central to next-generation drug discovery and development.

Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?sai-v

Recent Developments

September 2026: In Europe, Boehringer Ingelheim entered a licensing agreement with Owkin to use its AI research platform and patient data for cancer and immunology drug discovery, highlighting the growing role of AI-driven target identification and precision medicine.

August 2026: In North America, research demonstrated that AI tools can accelerate clinical trial execution, supporting applications in patient enrollment, data consolidation, trial operations, and automated clinical workflows.

July 2026: Globally, AI-designed drug candidates continued advancing through Phase II and Phase III clinical development, increasing industry focus on clinical validation, AI-generated molecules, target discovery, and regulatory acceptance.

June 2026: In North America and Europe, pharmaceutical companies increasingly adopted AI agents and generative AI for clinical trial design, protocol optimization, patient stratification, drug repurposing, and clinical data analysis.

June 2026: In Europe, Sanofi and Owkin expanded their collaboration around AI-powered drug discovery and development, focusing on patient data, precision medicine, biomarker discovery, and disease biology.

May 2026: In North America, AstraZeneca expanded its use of AI-powered research platforms to support target identification, biomarker discovery, drug development, and precision medicine.

April 2026: In Asia-Pacific, researchers continued advancing AI-based molecular design, protein engineering, virtual screening, toxicity prediction, and lead optimization, strengthening AI adoption across early-stage drug discovery.

March 2026: Globally, the industry increasingly focused on multimodal AI, foundation models, large language models, generative AI, digital twins, predictive toxicology, automated laboratory systems, and AI-enabled clinical development.

Mergers & Acquisitions
Owkin: Expanded its AI-powered drug discovery and precision medicine ecosystem through strategic collaborations with major pharmaceutical companies, focusing on patient data, target discovery, biomarker identification, and clinical development.

Boehringer Ingelheim: Strengthened its AI-enabled drug discovery capabilities through collaboration with Owkin, targeting oncology, immunology, patient data analytics, and AI-powered research.

Sanofi: Continued expanding its AI and digital drug discovery strategy through partnerships focused on precision medicine, disease biology, data analytics, and computational drug development.

AstraZeneca: Continued integrating AI platforms, machine learning, generative AI, and computational biology across target identification, drug design, biomarker discovery, and clinical development.

Industry Consolidation: Across North America, Europe, and Asia-Pacific, strategic activity is increasingly focused on generative AI, AI agents, foundation models, virtual screening, de novo molecular design, target identification, protein engineering, predictive toxicology, clinical trial optimization, biomarker discovery, precision medicine, digital twins, and automated drug development workflows.

Key Players
Alphabet (Google DeepMind) | Atomwise | BenevolentAI | BioMap | BioSymetrics | Deep Genomics | Euretos | Exscientia | IBM | Iktos | Others

Key Highlights
Alphabet (Google DeepMind) - Holds a 14.0% share, supported by advanced AI models such as AlphaFold, computational biology capabilities, and strategic integration of AI into drug discovery workflows.

Atomwise - Holds a 9.0% share, driven by AI-powered molecular screening, virtual screening technologies, and partnerships focused on accelerating small-molecule drug discovery.

BenevolentAI - Holds an 8.0% share, supported by its AI-enabled target identification, drug repurposing, and biomedical knowledge discovery platform.

BioMap - Holds a 6.0% share, strengthened by generative AI and protein intelligence technologies supporting therapeutic discovery and molecular design.

BioSymetrics - Holds a 5.0% share, driven by its AI-powered phenomics platform and integration of clinical and biomedical data for drug discovery.

Deep Genomics - Holds a 5.0% share, supported by AI-based analysis of RNA biology and development of precision therapeutic candidates.

Euretos - Holds a 4.0% share, driven by its AI-powered biomedical knowledge graph and data-analysis capabilities for target discovery and translational research.

Exscientia - Holds a 10.0% share, supported by its AI-driven drug design platform, automated discovery workflows, and computational approaches for accelerating candidate development.

IBM - Holds a 8.0% share, strengthened by enterprise AI, cloud computing, machine learning, and computational drug-discovery solutions.

Iktos - Holds a 6.0% share, driven by generative AI for molecular design, de novo drug discovery, and optimization of therapeutic candidates.

Others - Hold a combined 25.0% share, comprising Insilico Medicine, Recursion, Schrödinger, Insitro, Owkin, XtalPi, Valo Health, NVIDIA, and other emerging AI-driven drug discovery companies.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market?sai-v

Market Drivers
AI is accelerating drug discovery, reducing the time required for target identification, compound screening, and lead optimization.

Rising drug R&D costs are pushing pharmaceutical companies toward AI-powered platforms that improve efficiency and reduce development risks.

Generative AI is reshaping molecular design, enabling researchers to rapidly create and optimize potential drug candidates.

Growing demand for precision medicine is driving AI use in biomarker discovery, patient stratification, and personalized therapies.

Expanding biological and clinical datasets are creating greater demand for advanced AI and machine-learning analytics.

Increasing pharma-AI partnerships are accelerating the adoption of artificial intelligence across the drug development lifecycle.

Industry Developments
Generative AI is transforming molecule discovery, supporting faster design of novel therapeutic candidates.

AI-powered target identification is expanding, helping researchers uncover new disease mechanisms and therapeutic opportunities.

Predictive AI models are improving screening, toxicity assessment, and drug-property prediction.

Clinical trials are becoming more AI-driven, with applications in patient recruitment, trial design, and data analysis.

AI-enabled drug pipelines are expanding, with more computationally discovered candidates progressing toward clinical development.

Strategic collaborations are accelerating innovation, bringing together pharmaceutical expertise, biotechnology, and advanced AI capabilities.

Regional Insights
North America - 42.60% share: Strong pharmaceutical R&D, advanced AI infrastructure, and high technology adoption support regional leadership.

Europe - 28.40% share: Growing investments in biotechnology, AI research, and pharmaceutical innovation are strengthening market growth.

Asia Pacific - 21.30% share: Expanding pharmaceutical industries, increasing R&D activity, and rapid digitalization are creating significant opportunities.

Latin America - 4.50% share: Rising healthcare investment and emerging biotechnology capabilities are supporting AI adoption.

Middle East & Africa - 3.20% share: Increasing investment in healthcare technology and life-sciences infrastructure is supporting market development.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?sai-v

Key Segments
➥ By Technology

Machine Learning: Represents a significant technology segment, supporting drug discovery through predictive modeling, pattern recognition, molecular property prediction, and identification of promising drug candidates.

Deep Learning: Is an important technology segment, enabling advanced analysis of complex biological and chemical datasets for target identification, virtual screening, and optimization of potential therapeutics.

Natural Language Processing (NLP): Supports drug discovery by extracting actionable insights from scientific publications, clinical data, patents, and other large volumes of unstructured biomedical information.

Other Technologies: Include emerging AI approaches such as reinforcement learning, generative AI, and knowledge-based systems that are increasingly being integrated into drug discovery and development workflows.

➥ By Application

Drug Target Identification and Validation: Represents a major application area, as AI helps researchers identify disease-associated targets and assess their potential for therapeutic intervention.

Virtual Screening: Is a rapidly expanding application, using AI models to evaluate large compound libraries and prioritize molecules with a higher likelihood of demonstrating desired biological activity.

De Novo Drug Design: Supports the development of novel drug candidates by using AI to generate and optimize molecular structures based on specific therapeutic requirements.

Drug Optimization: Enables researchers to improve candidate molecules by assessing properties such as potency, selectivity, stability, and safety during the development process.

Preclinical Testing: AI applications help analyze experimental data, predict drug behavior, and support the evaluation of safety and efficacy before candidates advance to clinical studies.

Clinical Trial Design and Optimization: Uses AI to support patient selection, trial design, recruitment, and data analysis, helping improve the efficiency of clinical development programs.

Other Applications: Include biomarker discovery, drug repurposing, toxicity prediction, pharmacokinetic modeling, and personalized medicine, further expanding AI adoption across the drug development lifecycle.

Explore the report here: https://www.datamintelligence.com/research-report/ai-in-drug-discovery-and-development-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.